Get the Stockscreener App
0.00
100.00%
-7.62
After Hours:
1.08
1.08
+
Nls Pharmaceutics Ltd stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$7.62
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.97M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
0.00
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$33.70
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
0.00 | 3.97M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Is NLS Pharmaceutics AG Equity Warrant stock positioned well for digital economyQuarterly Risk Review & Daily Oversold Bounce Ideas - Newser
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Aktiellt
Is NLS Pharmaceutics AG stock a top momentum playJuly 2025 Final Week & Risk Managed Investment Signals - Newser
NLS Pharmaceutics : to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 - marketscreener.com
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs (PR Newswire) - Aktiellt
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy (PR Newswire) - Aktiellt
NewCelX Appoints EY as New Auditor Following Merger - TipRanks
NLSP appoints EY firm, dismisses CBIZ CPAs in post-merger shift - Stock Titan
Will NLS Pharmaceutics AG stock gain from lower inflationWeekly Investment Report & AI Enhanced Trade Execution Alerts - newser.com
What institutional flow reveals about NLS Pharmaceutics AG Equity WarrantJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Is NLS Pharmaceutics AG stock attractive for passive investorsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Is NLS Pharmaceutics AG stock supported by innovation pipelineJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
What candlestick patterns are forming on NLS Pharmaceutics AG2025 Pullback Review & Expert Curated Trade Ideas - newser.com
What to do if you’re stuck in NLS Pharmaceutics AG Equity WarrantStop Loss & Real-Time Volume Surge Alerts - newser.com
Will NLS Pharmaceutics AG Equity Warrant stock go up soonQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - newser.com
Can NLS Pharmaceutics AG stock attract ESG capital inflowsJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com
Heatmap analysis for NLS Pharmaceutics AG Equity Warrant and competitors - newser.com
Is NLS Pharmaceutics AG Equity Warrant stock a bargain at current levelsMarket Activity Summary & Breakout Confirmation Trade Signals - newser.com
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
Is NLS Pharmaceutics AG Equity Warrant stock near bottom after declineGap Down & Community Driven Trade Alerts - newser.com
Real time scanner hits for NLS Pharmaceutics AG Equity Warrant explainedWeekly Trade Recap & Precise Buy Zone Identification - newser.com
Will NLS Pharmaceutics AG continue its uptrendTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Will NLS Pharmaceutics AG Equity Warrant continue its uptrendJuly 2025 Outlook & Stepwise Trade Signal Implementation - newser.com
What the charts say about NLS Pharmaceutics AG todayQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Published on: 2025-11-12 22:54:02 - newser.com
Is NLS Pharmaceutics AG Equity Warrant stock a dividend growth opportunityTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Analyzing NLS Pharmaceutics AG Equity Warrant with multi timeframe chartsJuly 2025 Opening Moves & Community Driven Trade Alerts - newser.com
Head to Head Contrast: NLS Pharmaceutics (NASDAQ:NCEL) vs. Addex Therapeutics (NASDAQ:ADXN) - Defense World
Can NLS Pharmaceutics AG Equity Warrant recover in the next quarterQuarterly Trade Report & Risk Controlled Stock Pick Alerts - newser.com
NLS Pharmaceutics to execute 1-for-10 reverse share split - MSN
NewcelX Ltd. (NCEL) interactive stock chart - Yahoo Finance UK
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 - Investing.com
NewcelX Announces New CFO Appointment Following Merger - TipRanks
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
Neurology expert Prof. Ben-Hur joins NewcelX scientific board By Investing.com - Investing.com Nigeria
NLS Pharmaceutics AG stock trend forecast2025 Market Sentiment & Safe Entry Trade Reports - newser.com
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
Neurology expert Prof. Ben-Hur joins NewcelX scientific board - Investing.com
Should you wait for a breakout in NLS Pharmaceutics AGPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):